OBJECTIVE: The aim of this study was to examine the effects of perilipin gene (PLIN) polymorphisms on weight gain with rosiglitazone treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 160 type 2 diabetic patients were treated with rosiglitazone (4 mg/day) for 12 weeks in addition to their previous medications, which were unchanged. Four single nucleotide polymorphisms (SNPs) at the PLIN locus were genotyped: PLIN 6209T>C, PLIN 11482G>A, PLIN 13041A>G, and PLIN 14995A>T. RESULTS: Although fasting plasma glucose and HbA(1c) levels decreased; mean body weight increased significantly after rosiglitazone treatment. Among the four SNPs tested, only the PLIN 11482G>A polymorphism was associated with weight gain from rosiglitazone treatment. In addition, there was a significant difference in the increase in the body weight among the genotypes. Patients with the 11482A/A genotype showed less increase in body weight than those with other genotypes. CONCLUSIONS: These data suggest that genetic variations in the perilipin gene can affect weight gain associated with rosiglitazone treatment in patients with type 2 diabetes.
OBJECTIVE: The aim of this study was to examine the effects of perilipin gene (PLIN) polymorphisms on weight gain with rosiglitazone treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 160 type 2 diabeticpatients were treated with rosiglitazone (4 mg/day) for 12 weeks in addition to their previous medications, which were unchanged. Four single nucleotide polymorphisms (SNPs) at the PLIN locus were genotyped: PLIN 6209T>C, PLIN 11482G>A, PLIN 13041A>G, and PLIN 14995A>T. RESULTS: Although fasting plasma glucose and HbA(1c) levels decreased; mean body weight increased significantly after rosiglitazone treatment. Among the four SNPs tested, only the PLIN 11482G>A polymorphism was associated with weight gain from rosiglitazone treatment. In addition, there was a significant difference in the increase in the body weight among the genotypes. Patients with the 11482A/A genotype showed less increase in body weight than those with other genotypes. CONCLUSIONS: These data suggest that genetic variations in the perilipin gene can affect weight gain associated with rosiglitazone treatment in patients with type 2 diabetes.
Authors: David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Maria Laura De Marchis; Kunjan R Dave; Alfonso Bellia; Giuseppe Fogliame; Patrizia Ferroni; Giulia Donadel; Francesco Cacciatore; Pasquale Abete; Chuanhui Dong; Antonello Pileggi; Mario Roselli; Camillo Ricordi; Paolo Sbraccia; Fiorella Guadagni; Tatjana Rundek; Davide Lauro Journal: Pharmacogenomics Date: 2014-12 Impact factor: 2.533
Authors: Sophie Deram; Christiane Y Nicolau; Pablo Perez-Martinez; Isabel Guazzelli; Alfredo Halpern; Bernardo L Wajchenberg; Jose M Ordovas; Sandra M Villares Journal: J Clin Endocrinol Metab Date: 2008-09-23 Impact factor: 5.958
Authors: Toshihide Kawai; Maggie C Y Ng; M Geoffrey Hayes; Issei Yoshiuchi; Takafumi Tsuchiya; Heather Robertson; Nancy J Cox; Kenneth S Polonsky; Graeme I Bell; David A Ehrmann Journal: Diabetes Res Clin Pract Date: 2009-09-25 Impact factor: 5.602